Page last updated: 2024-12-07
phenylglucuronide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Phenylglucuronide is a glucuronide conjugate of phenol. It is formed in the liver by the enzyme UDP-glucuronosyltransferase (UGT) and is a major route of detoxification for phenol. Phenylglucuronide is excreted in urine and feces. It is studied because it is an important biomarker for exposure to phenol. Phenylglucuronide is also used as a substrate for the study of UGT activity.'
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 119239 |
| CHEBI ID | 177778 |
| SCHEMBL ID | 3224345 |
| MeSH ID | M0084480 |
Synonyms (10)
| Synonym |
|---|
| 16063-67-5 |
| CHEBI:177778 |
| phenyl d-glucopyranosiduronic acid |
| (2s,3s,4s,5r)-3,4,5-trihydroxy-6-phenoxyoxane-2-carboxylic acid |
| phenylglucuronide |
| d-glucopyranosiduronic acid, phenyl |
| SCHEMBL3224345 |
| phenyl glucopyranosiduronic acid |
| DTXSID60936351 |
| phenyl hexopyranosiduronic acid |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Saturation of benzene metabolism could limit the production of toxic species." | ( Hematotoxicity and concentration-dependent conjugation of phenol in mice following inhalation exposure to benzene. Nerland, DE; Wells, MS, 1991) | 0.28 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Of the total phenol in the aquarium water of goldfish exposed previously to phenol for 48 h, 41% was found to be phenylglucuronide when fish were placed in a phenol-free medium and were dosed hourly for 8 h with D-saccharic acid 1,4-lactone to inhibit beta-glucuronidase activity in the intestine." | ( Hydrolysis of the biliary glucuronic acid conjugate of phenol by the intestinal mucus/flora of goldfish (Carassius auratus). Knights, B; Layiwola, PJ; Linnecar, DF, 1983) | 0.48 |
| " The immersion dosing method employed for the experiment is discussed with relation to the natural habitat of the fish." | ( The biotransformation of [14C]phenol in some freshwater fish. Layiwola, PJ; Linnecar, DF, 1981) | 0.26 |
| " Dividing the dose-response curve data obtained with in vitro PBK-based reverse dosimetry, with the CSAF provided a dose-response curve that reflects the consequences of the interindividual variability in phenol kinetics for the developmental toxicity of phenol." | ( Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity. Punt, A; Rietjens, IMCM; Spenkelink, B; Strikwold, M; Woutersen, RA, 2017) | 0.46 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (61.11) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.13) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||